Pharma mega mergers a boon for Patheon's restructuring service, says CEO
The global economic downturn, impending blockbuster patent expiries and the wave of consolidation sweeping the pharmaceutical industry will drive demand for Patheon’s restructuring service according to CEO Wesley Wheeler.
Wheeler spoke with Outsourcing-pharma at Interphex 2009 in New York, US about the considerable opportunities created for Patheon’s restructuring service by the slew of recent billion dollar drug industry M&A activity, taking Pfizer's move for Wyeth and Roche's deal for Genentech among the most high profile examples.
He also said that facility acquisitions Patheon makes through its restructuring service will bolster its global network and further strengthen its position in a drug market focused on reducing manufacturing costs and improving its reach into emerging global markets.
